Navigation Links
Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Date:4/8/2013

je una valoración precisa de la plataforma epigenética.

El objetivo de la desincorporación es dividir el programa clínico de RVX-208 (Resverlogix) de la plataforma epigenética (RVX Therapeutics). Así, este proceso creará entornos empresariales diferentes, como el de que Resverlogix está preparado estructuralmente para la adquisición al tiempo que el valor futuro de RVX Therapeutics se conseguirá por medio de un modelo empresarial de licencia y/o asociación.

Esto presenta el potencial para desvelar el valor futuro para RVX Therapeutics por medio de la investigación y desarrollo del mecanismo epigenético, creando un flujo de royalties potenciales desde RVX-208. La mejora del valor de los accionistas a largo plazo se suministra a través de las valoraciones directas relacionadas con cualquier acuerdo de licencia y asociación.

Además, la nueva estructura minimizará las diluciones futuras que la corporación necesite de capital de valores adicional.

Resverlogix seguirá centrándose en el desarrollo clínico de RVX-208, su molécula pequeña para el tratamiento de la ateroesclerosis por medio de los aumentos terapéuticos en Apo A-1. Además, Resverlogix seguirá con su ensayo clínico relacionado con RVX-208 para la diabetes y en breve lanzará el ensayo clínico para la enfermedad de Alzheimer.

RVX Therapeutics se centrará en la investigación y desarrollo relacionado con el innovador fármaco al mejorar la plataforma epigenética en múltiples enfermedades, incluyendo la autoinmune y oncología, excluyendo Apo A-1 y la tecnología RVX-208.

Está previsto que los directores y responsables senior de RVX Therapeutics sigan formando el conjunto de los directores actuales y responsables senior de Resverlogix.

Los accionistas de Resverlogix recibirán una acci
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
2. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
3. Aratana Therapeutics Adds To Drug Development Team
4. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
5. Novira Therapeutics Completes $25 Million Series A Financing
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
8. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
9. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
10. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
11. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 25, 2014 Berkshire ... is pleased to announce the release of the ... highest level of contamination containment in critical processing ... 3 and higher cleanroom environments, ValuSeal® IonX™ is ... knit laundered wiper that continues Berkshire’s innovative focus ...
(Date:10/25/2014)... -- Research and Markets has announced the ... Research Area & by End User - Global Forecast ... In this report, the global epigenetics market is ... end users. The product segments of the epigenetics market ... kits, and reagents. The subsegments of the enzymes product ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... (OTC Bulletin Board: CHBT) (,China-Biotics", "the,Company"), a leading ... and distribution of probiotics products,today announced its financial ... year, ended June 30, 2008., First ... 19.5% year-over-year to $11.4 million -- Gross ...
... ... Aug. 14 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... science of healthy aging, today announced,financial results for the quarter ... June 30, 2008 was $691,000, compared with,$471,000 reported in the ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... A custom-built, $2.5 million "split magnet" system with the potential ... made its debut at the National High Magnetic Field Laboratory ... at 25 tesla, easily besting the 17.5 tesla French record ... for early 20th-century inventor and engineer Nikola Tesla, is a ...
... as a preventative measure only achieve a short-term effect with ... up with even more aphids than untreated fields. This has ... of Wrzburg in the scientific journal PLoS One . ... triticale fields? This is what the biologists at the Department ...
... widely known PSA blood test for prostate cancer in men ... for breast cancer, the most common form of cancer in ... the ACS journal Analytical Chemistry . Chien Chou ... the test also is a potential biomarker of breast cancer ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Fewer aphids in organic crop fields 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: